Boehringer Ingelheim makes million-euro investment in fight against antibiotic resistance

The pharmaceutical firm is investing EUR 30m in a new biotech company focused on precision medicine to treat infections.
Photo: Boehringer Ingelheim / PR
Photo: Boehringer Ingelheim / PR
by andreas lønstrup, translated by daniel pedersen

German pharmaceutical firm Boehringer Ingelheim is investing EUR 30m to combat drug-resistant bacteria. Forming an alliance with Evotec and Biomérieux, the firms have established Aurobac Therapeutics, a biotech firm with a precision medicine approach to infection treatment, as reported by Fierce Biotech.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading